search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- 1. Accounting Policies
- 2. Financial risk management
- 3. Segmental information
- 4. Exceptional operating items
- 5. Operating profit/(loss)
- 6. Employees and Directors
- 7. Finance Income and costs
- 8. Taxation on Loss on ordinary activites
- 9. Loss for the financial year
- 10. Earnings/(Loss) per Share
- 11. Goodwill
- 12. Intangible assets
- 13. Property, plant and equipment
- 14. Investments
- 15. Inventories
- 16. Trade and other receivables
- 17. Trade and other payables
- 18. Borrowings
- 19. Non-current tax
- 20. Financial Instruments
- 21. Called-up share capital
- 22. Options and Warrants over Shares of Sinclair Pharma plc
- 23. Share-based payments
- 24. Other Reserves
- 25. Cash Flows from Operating Activities
- 26. Operating lease commitments
- 27. Capital Commitments
- 28. Related Party Transactions
- corporate advisors
25. CASH FLOW FROM OPERATING ACTIVITIES
Group |
Company |
||||
2008 |
2007 |
2008 |
2007 |
||
£'000 |
£'000 |
£'000 |
£'000 |
||
| Profit/(loss) before tax | 1,574 |
(3,980) |
149 |
(8,664) |
|
| Finance income | (447) |
(95) |
(1,462) |
(856) |
|
| Finance costs | 741 |
129 |
466 |
56 |
|
| Share-based payment – value of employee services | 678 |
240 |
118 |
122 |
|
| Depreciation | 572 |
442 |
— |
— |
|
| Amortisation of intangible assets | 1,483 |
975 |
68 |
68 |
|
| Impairment charges | 381 |
28 |
1,985 |
5,100 |
|
| Partial waiver of loan account | — |
— |
571 |
— |
|
| Profit on disposal of property, plant and equipment | (15) |
(9) |
— |
— |
|
| Profit on sale of product rights | (35) |
(1,237) |
— |
— |
|
| (Decrease)/increase in provision for doubtful debts | (696) |
749 |
— |
— |
|
| Exchange (gain)/loss | (4,424) |
611 |
(4,057) |
821 |
|
| Changes in working capital (excluding effects of acquisitions) | (188) |
(2,149) |
(2,162) |
(3,353) |
|
| (Increase)/decrease in inventories | (888) |
484 |
— |
— |
|
| (Increase)/decrease in receivables | (4,528) |
(358) |
(2,311) |
872 |
|
| Increase/(decrease) in payables | 2,676 |
651 |
(214) |
(306) |
|
| (Decrease)/increase in deferred income | (322) |
185 |
— |
— |
|
| Net cash outflow from operations | (3,250) |
(1,185) |
(4,687) |
(2,787) |
|
Non-cash transactions
During the year, the Group disposed product rights of £455,000 for which no cash proceeds were received. The disposal proceeds being used to reduce the outstanding balance due for the purchase of other product rights with the same party.